Methotrexate (MTX), in clinical practice. Other factors associated were also investigated.

Methods: An inception cohort of GCA was assembled in the out-patient clinic at Hospital Clinico San Carlos, including patients from the date of diagnosis (Jan-1991 until Sept-2013), and followed-up until Sept-2014. Main outcome: relapses defined as after an objective improvement, patient has again symptoms or signs of GCA with high ESR and the need to increase corticosteroids at least 10mg. The independent variable was exposure to MTX over time. Covariables: Sociodemographic, clinical, and treatment. Incidence rates of relapses (IR) per 100 patient-years with their 95% confidence intervals [CI] were estimated using survival techniques. Time of exposure comprised the period from diagnosis until: lost of follow-up, main outcome, exposure to MTX or the end of the study. MTX influence on IR was analyzed by multivariable Cox models.

Results: 168 patients were included (675 patient-years). 80% of them were female, with a mean age of 76±7 years. 65% of the patients were on MTX, with mean dose of 10 mg/week. 31% of patients had relapses with an IR of 12 [9.6–14.9]. The median number of relapses was 1 [1–2], with a median lag time of 1.6 [0.6–6.3] years. In the multivariate analysis, exposure to MTX had less risk of flaring compared to those never on MTX ($p<0.05$). Other variables included in the final model were: visual alterations, constitutional symptoms or malaise at clinical presentation of GCA.

Conclusions: The use of MTX seems to decrease the risk of recurrences. We also found other factors influencing on flares.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6118

THU0310 FREQUENCY OF RELAPSES AND TREATMENT DISCONTINUATION DURING LONG-TERM FOLLOW-UP OF PATIENTS WITH GIANT CELL ARTERITIS

C. Tsalapaki, A. Lazarini, K. Antonatou, K. Thomas, K. Klavdianou, C. Koutsianas, D. Vassilopoulos. *Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens School of Medicine, Hippokraton General Hospital, Athens, Greece*

Background: There are limited data regarding the long term outcomes of patients with giant cell arteritis (GCA) in the modern therapeutic era.

Objectives: To evaluate relapse, treatment discontinuation and complication rates in GCA patients during long term follow-up.

Methods: A retrospective systematic chart review of GCA patients who were followed in an Academic Rheumatology Unit between 2002 to 2016 was performed. Demographic, clinical, laboratory and treatment data were collected and analyzed.

Results: 53 GCA patients were included in the study. 62% (n=33) were women with a mean age at diagnosis of 73±8.8 years and median duration of symptoms of 1.3 months. 41 patients (77%) had biopsy proven GCA while in 5 patients (9%) there was evidence of large vessel involvement. At presentation, the most common symptoms were headache (60%), fever (51%), scalp tenderness (47%), jaw claudication (39%), visual disturbances (23%), polymyalgia rheumatica symptoms (9%) and vision loss (6%). Regarding laboratory data at baseline, the median ESR and CRP were 101 mm/h and 50 mg/dl respectively while the mean hemoglobin (Hb) and platelet (PLT) count was 11.3±1.2 g/dl and 381.000±134.000, respectively. All patients were initially treated with tapering doses of pos steroids (mean start prednisolone dose: 42±12 mg/day) while 2 patients (4%) were given IV steroid pulses. During follow-up (3.1±2.7 years), for patients with did not adequately respond or could not tolerate steroids, non-biologic (n=12, 23%) or biologic DMARDs (n=4, 7%) were added. Relapses requiring change in immunosuppressive therapy occurred in more than half of patients (n=28, 53%); among these 67% were laboratory and 56% clinical relapses. Osteoporosis (17%), cataracts (7%), fractures (4%) and avascular necrosis (2%) developed during chronic steroid treatment. At the last follow-up visit, 39% (n=21) of patients had discontinued steroids and 31% (n=17) all treatments. Comparing the group of patients who had discontinued treatment (D/C group) to those who were unable to stop therapy (continued therapy group), there were no statistically significant differences (age, duration of symptoms at diagnosis, initial steroid dose, baseline and follow-up ESR, CRP, Hb and platelet values, relapses, co-administration of DMARDs, comorbidities), except from gender (females: D/C group=41%, continued therapy group=72%, $p=0.03$). Kaplan-Meier analysis also showed that the median time to discontinuation of treatment was longer in females compared to males (log rank $p=0.018$).

Conclusions: In this long-term follow-up study, relapses occurred in more than half of GCA patients while only one out of three patients were able to discontinue all therapies. Among different variables, only male sex was associated with earlier treatment discontinuation.

Acknowledgements: Supported by research grants from the Special Account for Research Grants (S.A.R.G.), National and Kapodistrian University of Athens, Athens, Greece.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6115

THU0311 FECAL MICROBIOTA IN BEHÇET'S SYNDROME PATIENTS WITH MUCOCUTANEOUS AND UVEITIS INVOLVEMENT

D. Tecer¹, F. Gogus¹, A. Kalkanç², M. Erdogan², S. Coban³, M. Hasanreisoglu⁴, T. Karakan⁵. *¹Department of Physical Medicine and Rehabilitation, Division of Rheumatology; ²Department of Medical Microbiology; ³School of Medicine phase 3 student; ⁴Department of Ophthalmology; ⁵Department of Gastroenterology, Gazi University, Faculty of Medicine, Ankara, Turkey*

Background: Innate immunity has a major role in the pathogenesis of Behçet's syndrome. The gut microbiota is an active component of the immune system. It plays an important role in the formation of the immune system in the early life and in the continuation of immune homeostasis through the life. Dysbiosis, imbalance in the gut microbiota, can lead to many serious metabolic and inflammatory pathologies

Objectives: We aimed to investigate the gut microbiota structure in Behçet's syndrome patients with mucocutaneous and uveitis involvement only.

Methods: 6 patients with Behçet's syndrome with uveitis, 12 patients with familial Mediterranean fever (FMF) and 9 patients with Crohn's disease (CD) and 10 healthy controls were included. Patients, positive and healthy controls were excluded if they had one of the following combined diseases/situations: a) gastrointestinal surgical history (e.g. bariatric surgery, gastrectomy or colectomy), b) antibiotic or probiotics use in the last 3 months, c) specific dietary restriction, d) malignancy, e) additional autoimmune disease or inflammatory bowel disease. Total DNA was extracted from fecal samples using the QIAamp DNA stool Mini Kit following the manufacturer's instructions (Qiagen). Next generation sequencing of 16S rRNA gene was performed using Ion Torrent Technology. Partial 16S rRNA sequences were amplified from extracted DNA using the 16S Metagenomics Kit (Life Technologies). The integrity of the PCR amplicons was analyzed by gel electrophoresis. PCR products were purified using AMPure XP DNA purification beads and Invitrogen DynaMag magnet apparatus. DNA concentration of the amplified sequence was equalized through the Qubit System (Life Technologies). The libraries were created by using the Ion Plus Fragment Library Kit. Barcodes were also added to each sample using the Ion Express Barcode Adapters Kit. Emulsion PCR was carried out using the Ion One Touch 2 machine. Sequencing of the amplicon libraries was carried out on a 318 chip the Ion Torrent Personal Genome Machine System and Ion PGM Hi-Q kit. 16S rRNA sequences were analyzed by Ion Reporter Software.

Results: In healthy subjects, fecal microbiota consisted predominantly of Bacteroidetes (53.2%) including Bacteroides and Prevotella genera. Firmicutes such as Bacilli, Clostridia, followed, consisting 31.2% of the bacterial community. Fecal bacterial flora of patients with Behçet's syndrome consisted of Firmicutes (45%), Proteobacteria (23%) such as Enterobacteriaceae and Prevotellaceae, and Bacteroidetes (10%). FMF cases were found to be colonized by Firmicutes (39.3%), Bacteroidetes (32.2%) and Proteobacteria (13.6%) predominantly. CD cases were colonized by Enterobacteriaceae (43%), and other Proteobacteria groups, followed by Bacteroidetes (15.4%) and Firmicutes (8.8%).

Conclusions: Fecal flora of patients with Behçet's syndrome and of positive control groups (FMF and CD) differed significantly from that of healthy controls. In a subgroup of patients with Behçet's disease with uveitis and mucocutaneous involvement only, firmicutes species seem to be the dominant bacterial fecal flora.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6541

THU0312 PERFORMANCE CHARACTERISTICS AND PREDICTORS OF TEMPORAL ARTERY ULTRASOUND AND BIOPSY FOR THE DIAGNOSIS OF GIANT CELL ARTERITIS IN A REAL WORLD POPULATION; A PROSPECTIVE COHORT STUDY

R. Conway¹, S. Di Bello¹, L. O'Neill¹, G.M. McCarthy², C.C. Murphy³, D.J. Veale¹, U. Fearon⁴, R.P. Killeen⁵, E.J. Heffernan⁵, E.S. Molloy¹. *¹Rheumatology, St Vincents University Hospital; ²Rheumatology, Mater Misericordiae University Hospital; ³Ophthalmology, Royal College of Surgeons in Ireland; ⁴Molecular Rheumatology, Trinity College Dublin; ⁵Radiology, St Vincents University Hospital, Dublin, Ireland*

Background: The diagnosis of giant cell arteritis (GCA) remains a clinical one. Temporal artery (TA) ultrasound (US) has been proposed as a new diagnostic tool in GCA.

Objectives: To assess the performance characteristics of TA US and biopsy in routine clinical practice.

Methods: All patients presenting with suspected GCA to our institutions are recruited to a prospective registry. Patients who had both a TA US and biopsy performed at the time of presentation were included in the current study. US was performed by 2 radiologists. The performance characteristics of both tests were compared to physician diagnosis at six months following presentation. Predictive factors for positive US and biopsy were explored in univariate and multivariable logistic regression analyses.

Results: 162 patients were included, 123 (76%) with GCA. Mean (SD) duration of glucocorticoids was 6.6 days (19.4) at the time of TA US and 6.2 days (8.4) at the time of TA biopsy. US had a sensitivity of 52.8% (95% CI 43.7, 61.9) and specificity of 71.8% (95% CI 54.9, 84.5). There were 11 false positive US results; 5 with migraine, 2 other vasculitides, 2 local infections, 2 malignancies. Biopsy

had a sensitivity of 48.8% (95% CI 39.7, 57.9) and specificity of 97.4% (95% CI 84.9, 99.9). A hypothetical sequential strategy of US followed by biopsy in the case of negative US had a sensitivity of 78.9% (95% CI 70.1, 85.5) and specificity of 71.8% (95% CI 54.9, 84.5), equivalent to a simultaneous testing strategy. Time on glucocorticoids did not significantly impact the results of US or biopsy. The only factor independently predictive of a positive US was male sex (OR 5.53, 95% CI 2.72 to 11.22, $p<0.001$). The only factor independently predictive of a positive biopsy was jaw claudication (OR 2.40, 95% CI 1.11, 5.21, $p=0.027$).

Table 1. Performance Characteristics of Ultrasound, Biopsy, and Combination Strategies

Strategy	Sensitivity	Specificity	PPV	NPV	PLR	NLR
Ultrasound alone	52.8	71.8	85.6	32.6	1.87	0.66
Biopsy alone	48.8	97.4	98.0	37.6	19.02	0.53
Sequential (Biopsy only if US positive)	22.8	97.4	96.6	28.6	8.88	0.79
Sequential (Biopsy only if ultrasound negative)	78.9	71.8	89.8	51.9	2.80	0.29
Simultaneous	78.9	71.8	89.8	51.9	2.80	0.29
Procedure, glucocorticoid duration						
Ultrasound, all, n=162	52.8	71.8	85.6	32.6	1.87	0.66
Ultrasound, 0 days, n=80	51.9	76.9	82.4	43.5	2.25	0.63
Ultrasound, >0 ≤3 days, n=27	46.2	100	100	6.0	Infinity	0.54
Ultrasound, >3 ≤7 days, n=25	60.0	40.0	80.0	20.0	1.00	1.00
Ultrasound, >7 ≤14 days, n=18	64.3	50.0	81.8	28.6	1.29	0.71
Ultrasound, >14 days, n=12	44.4	100	100	37.5	Infinity	0.56
Biopsy, all, n=162	48.8	97.4	98.0	37.6	19.02	0.53
Biopsy, 0 days, n=53	46.9	100	100	55.3	Infinity	0.53
Biopsy, >0 ≤3 days, n=24	66.7	83.3	92.3	45.5	4.00	0.40
Biopsy, >3 ≤7 days, n=38	47.1	100	100	18.2	Infinity	0.53
Biopsy, >7 ≤14 days, n=29	47.8	100	100	33.3	Infinity	0.52
Biopsy, >14 days, n=18	37.5	100	100	17.0	Infinity	0.63

Conclusions: TA US is a useful tool in the diagnosis of GCA; however false positive tests occur in 7% and thorough clinical assessment remains crucial. Prior glucocorticoid treatment has no clear impact on results.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4629

THU0313 INFERIOR AND SUPERIOR VENA CAVA THROMBOSIS IN BEHÇET'S DISEASE. MOROCCAN EXPERIENCE

F.Z. Alaoui¹, M. Moudatir². ¹Internal medicine; ²12 rue la saone, Polo, University hospital ibn rochd, Casablanca, Morocco

Background: Behçet's disease (BD) is a systemic disorder with a vascular tropism where the vessels might be affected. Venous thrombosis is the most common vascular complication. Among its locations, vena cava thrombosis (VCT) are rare but can be life-threatening. The purpose of this work is to specify the frequency of VCT in the course of Behçet's disease in morocco and to analyse epidemiological, clinical and therapeutic modalities.

Objectives: This retrospective study was conducted in the internal medicine department of the University Hospital IbnRochd of Casablanca, over a period of thirty-five years between 1980 and 2016.

Methods: Where included 1618 cases of Behçet's disease, all diagnosed in our service and meeting the diagnosis criteria as defined by the international study group (ISG) for Behçet's disease.

Results: 52 patients with VCT – 47 men and 4 women - were gathered during this period, representing a rate of 3.30% of 1572 cases, with a mean age of 35 years (ranges 17–54). The diagnosis of VCT and BD was concomitant in 10 cases and occurred during the course of the disease in 42 cases after an average of 6 years of evolution. Among the localization. Inferior VCT is the most frequent localization (32 patients, including 15 cases of Budd- Chiari syndrome). The superior VCT was reported in 24 patients, whereas 5 patients had both a superior and inferior VCT.Vena cava thrombosis was associated with deep venous thrombosis (DVT) of the lower limbs in 24 cases and with an aneurysm in 7 cases (pulmonary artery: 4 cases, femoral artery: 2 cases, abdominal aorta; 1 case). Regarding the therapeutic modalities, 41 patients were under anti-coagulant treatment, 45 patients received corticosteroids and 51 of the patients were under immunosuppressive agents (cyclophosphamide,azathioprine).

The evolution was significantly improved after the introduction of the immunosuppressive therapy, which were firstly initiated in 2006.

Conclusions: Vena cava thrombosis in the context of Behçet's disease is a very serious pathology threatening the patient's vital and functional prognosis. Preventive measures, early diagnosis and effective treatment are the keys to a successful management of such complications' risks.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6965

THU0314 RADIOLOGIC ACTIVITY IS THE MAJOR DETERMINANT FOR PHYSICIANS WHILE DECIDING ACTIVE DISEASE IN TAKAYASU ARTERITIS

G. Kenar¹, P. Cetin², H. Yarkan¹, B. Zengin¹, G. Can¹, M. Birlik¹, F. Onen¹. ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir; ²Rheumatology, Dumlupinar University, Kutahya, Turkey

Background: There are no valid follow-up parameters in the assessment of disease activity in Takayasu arteritis (TA).

Objectives: We investigated the impact of incorporation of vascular imaging into ITAS in the assessment of disease activity in TA.

Methods: 52 patients who fulfilled the ACR criteria were included in the study. PGA, Kerr et al.'s criteria and ITAS2010/ITAS-A scores were evaluated in all patients in serial visits. All the patients were followed using 3–6 monthly B-mode/Doppler ultrasonography (USG) and 6–12 monthly magnetic resonance angiography (MRA).

Radiological activity (Rad) was defined based on the presence of any of the 3 parameters including new vessel involvement by any technique (5 points),increase in vessel wall thickness on USG (3 points) and vessel wall edema on MRA (3 points).Then we incorporated these scores with ITAS-A to obtain a composite disease activity index (ITAS2010-A-Rad) (Table 1). Active disease was defined as ITAS-A-Rad >4 points.

Results: Total 410 visits of 52 TA patients (mean age 50.7 yrs, F: 92.3%, mean follow-up duration:6.4±2.9 yrs) were evaluated. Radiological assessment was done in 359 visits (by USG in 271 and by MRA in 190). Patients were categorized as having active disease in 194 visits (47.4%) according to PGA and 72 visits (17.5%) according to Kerr et al. criteria.The agreement between them was fair (66%, κ : 0.29). Radiological activity was determined in 105 out of 359 visits (29.2%). The total agreement between radiological activity and Kerr et al. criteria was 83% (κ : 0.58). It was found to be 76% (κ : 0.52) between radiological activity and PGA. Mean ITAS-A-Rad scores were found to be significantly higher in visits with active disease compared to visits with inactive disease according to both PGA and Kerr et al. criteria (Table 2). The ITAS-A-Rad was significantly correlated with all the other activity parameters including ITAS2010, ITAS-A, and APRs. There were 43 visits with new vessel involvement by any radiologic technique; all visits included patients with active disease based on both PGA and Kerr et al. criteria. Whereas in 50% of these visits, patients had normal CRP, and %49 had normal ESR. The agreement between ITAS2010 and PGA was fair (69%, κ : 0.38).When APR was added (ITAS-A), it did not improve (68%, κ : 0.34). But the agreement between

Table 1. The definition of ITAS-A-Rad Score

Clinical	ITAS2010	
Laboratory	APR	ESR
		CRP
Radiology	Radiological activity	New vessel involvement with any radiological method
		B-mode Doppler USG
		MRA
Total	ITAS-A-RAD Score	

ITAS-A-Rad Score >4 → Activity.

Table 2. Response to change: The mean ITAS-A-Rad scores in serial visits

Visit no	ITAS-A-Rad score (mean±SD)		P
	PGA: active	inactive	
1	16.72±6.3	5.25±4.9	<0.001*
2	6.23±4.6	1.92±3.8	<0.001*
3	5.12±3.3	1.40±1.88	<0.001*
4	4.11±2.47	1.60±1.72	<0.001*
5	6.36±5.6	1.36±1.7	<0.001*
6	3.20±2	2.95±39	0.29
7	4±2.3	1.76±2.7	<0.001*
8	5.3±3.8	1.3±1.77	<0.001*
9	4.33±6.02	1.21±2.3	0.02*
10	6.67±4.5	1.51±2.3	0.06
11	4±2.7	1.10±0.99	0.028*